Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Nicotine Delivery Systems | 19 | 2025 | 214 | 7.060 |
Why?
|
| Tobacco Products | 18 | 2024 | 199 | 6.580 |
Why?
|
| Social Media | 10 | 2025 | 58 | 4.810 |
Why?
|
| Sexual and Gender Minorities | 11 | 2025 | 54 | 4.360 |
Why?
|
| Vaping | 12 | 2025 | 138 | 4.190 |
Why?
|
| Nicotine | 13 | 2024 | 86 | 3.220 |
Why?
|
| Substance-Related Disorders | 9 | 2025 | 187 | 3.120 |
Why?
|
| Cigarette Smoking | 5 | 2022 | 82 | 2.900 |
Why?
|
| Tobacco Use | 11 | 2025 | 103 | 2.900 |
Why?
|
| Smoking Cessation | 9 | 2022 | 412 | 2.610 |
Why?
|
| Adolescent | 25 | 2025 | 3165 | 2.040 |
Why?
|
| Tobacco Use Disorder | 4 | 2022 | 117 | 1.830 |
Why?
|
| Minority Groups | 6 | 2025 | 75 | 1.740 |
Why?
|
| Young Adult | 21 | 2025 | 2804 | 1.700 |
Why?
|
| Smoking | 7 | 2022 | 476 | 1.570 |
Why?
|
| Stress, Psychological | 5 | 2025 | 229 | 1.550 |
Why?
|
| Humans | 59 | 2025 | 28581 | 1.520 |
Why?
|
| Intention | 4 | 2023 | 78 | 1.510 |
Why?
|
| Smokers | 5 | 2022 | 128 | 1.510 |
Why?
|
| Male | 37 | 2025 | 13771 | 1.410 |
Why?
|
| Adult | 28 | 2025 | 7922 | 1.380 |
Why?
|
| Female | 37 | 2025 | 15471 | 1.330 |
Why?
|
| Cannabis | 2 | 2024 | 46 | 0.970 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2025 | 31 | 0.910 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 988 | 0.880 |
Why?
|
| Lung Injury | 1 | 2023 | 32 | 0.810 |
Why?
|
| Adolescent Behavior | 2 | 2025 | 68 | 0.760 |
Why?
|
| Cotinine | 2 | 2019 | 45 | 0.750 |
Why?
|
| Binge Drinking | 1 | 2021 | 13 | 0.690 |
Why?
|
| Peer Group | 1 | 2021 | 37 | 0.680 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2021 | 41 | 0.680 |
Why?
|
| Health Equity | 1 | 2020 | 15 | 0.670 |
Why?
|
| Urban Population | 3 | 2025 | 86 | 0.650 |
Why?
|
| Health Status Disparities | 1 | 2020 | 65 | 0.650 |
Why?
|
| Health Behavior | 2 | 2020 | 158 | 0.640 |
Why?
|
| Rural Population | 3 | 2025 | 120 | 0.630 |
Why?
|
| Biomedical Research | 1 | 2020 | 98 | 0.630 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 389 | 0.620 |
Why?
|
| Research Design | 1 | 2020 | 185 | 0.620 |
Why?
|
| Homosexuality, Female | 1 | 2019 | 4 | 0.610 |
Why?
|
| Bisexuality | 1 | 2019 | 4 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 100 | 0.610 |
Why?
|
| Behavior, Addictive | 1 | 2019 | 23 | 0.600 |
Why?
|
| Homosexuality, Male | 1 | 2019 | 17 | 0.600 |
Why?
|
| Health Promotion | 1 | 2020 | 177 | 0.590 |
Why?
|
| Prevalence | 4 | 2022 | 510 | 0.590 |
Why?
|
| Marijuana Use | 1 | 2018 | 41 | 0.560 |
Why?
|
| Social Networking | 1 | 2017 | 10 | 0.550 |
Why?
|
| Blood Donors | 1 | 2017 | 4 | 0.540 |
Why?
|
| Pharmaceutical Preparations | 2 | 2023 | 48 | 0.530 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 65 | 0.530 |
Why?
|
| United States | 7 | 2025 | 2201 | 0.520 |
Why?
|
| Surveys and Questionnaires | 6 | 2025 | 994 | 0.520 |
Why?
|
| Self Efficacy | 1 | 2017 | 79 | 0.510 |
Why?
|
| Social Support | 1 | 2017 | 128 | 0.510 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 10 | 0.510 |
Why?
|
| Outpatients | 1 | 2016 | 44 | 0.500 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 46 | 0.500 |
Why?
|
| Pharmacists | 1 | 2016 | 74 | 0.480 |
Why?
|
| Health Maintenance Organizations | 3 | 2011 | 9 | 0.460 |
Why?
|
| San Francisco | 3 | 2019 | 12 | 0.450 |
Why?
|
| Self Report | 3 | 2020 | 121 | 0.450 |
Why?
|
| California | 4 | 2025 | 70 | 0.440 |
Why?
|
| Kidney | 1 | 2016 | 286 | 0.440 |
Why?
|
| Tobacco | 3 | 2023 | 87 | 0.420 |
Why?
|
| Pandemics | 4 | 2021 | 196 | 0.400 |
Why?
|
| Cities | 2 | 2021 | 16 | 0.350 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2011 | 14 | 0.340 |
Why?
|
| Job Satisfaction | 1 | 2011 | 24 | 0.340 |
Why?
|
| Prospective Studies | 3 | 2024 | 1272 | 0.330 |
Why?
|
| Diazepam | 1 | 2010 | 3 | 0.330 |
Why?
|
| Longitudinal Studies | 3 | 2025 | 426 | 0.330 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 7 | 0.330 |
Why?
|
| Flavoring Agents | 4 | 2023 | 15 | 0.300 |
Why?
|
| Primary Health Care | 1 | 2011 | 160 | 0.300 |
Why?
|
| Saliva | 2 | 2019 | 96 | 0.300 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 164 | 0.290 |
Why?
|
| Appetite Depressants | 2 | 2005 | 2 | 0.290 |
Why?
|
| Cyclobutanes | 2 | 2005 | 3 | 0.290 |
Why?
|
| Menthol | 3 | 2023 | 18 | 0.270 |
Why?
|
| Pilot Projects | 2 | 2020 | 458 | 0.270 |
Why?
|
| Sex Factors | 2 | 2018 | 467 | 0.260 |
Why?
|
| Social Stigma | 1 | 2025 | 15 | 0.230 |
Why?
|
| Fraud | 1 | 2025 | 5 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 114 | 0.230 |
Why?
|
| Marijuana Smoking | 1 | 2025 | 35 | 0.230 |
Why?
|
| Weight Loss | 1 | 2005 | 83 | 0.220 |
Why?
|
| Cognitive Dissonance | 1 | 2024 | 2 | 0.210 |
Why?
|
| Patient Selection | 1 | 2025 | 149 | 0.210 |
Why?
|
| Hallucinogens | 1 | 2024 | 14 | 0.210 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2023 | 12 | 0.210 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 216 | 0.200 |
Why?
|
| Product Labeling | 1 | 2023 | 10 | 0.200 |
Why?
|
| Obesity | 3 | 2005 | 675 | 0.200 |
Why?
|
| Respiratory System | 1 | 2022 | 13 | 0.200 |
Why?
|
| Robotics | 1 | 2023 | 43 | 0.190 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 74 | 0.190 |
Why?
|
| Social Behavior | 2 | 2020 | 54 | 0.190 |
Why?
|
| Tobacco, Smokeless | 1 | 2022 | 43 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2022 | 209 | 0.180 |
Why?
|
| Policy | 1 | 2021 | 13 | 0.180 |
Why?
|
| Telemedicine | 1 | 2025 | 187 | 0.180 |
Why?
|
| Energy Metabolism | 2 | 2021 | 206 | 0.180 |
Why?
|
| Odds Ratio | 1 | 2022 | 236 | 0.180 |
Why?
|
| Conservation of Water Resources | 1 | 2021 | 3 | 0.180 |
Why?
|
| Attitude | 1 | 2021 | 44 | 0.170 |
Why?
|
| Counseling | 1 | 2021 | 57 | 0.170 |
Why?
|
| Search Engine | 1 | 2020 | 7 | 0.170 |
Why?
|
| Perception | 1 | 2021 | 90 | 0.170 |
Why?
|
| Risk-Taking | 1 | 2021 | 61 | 0.170 |
Why?
|
| Taxes | 1 | 2020 | 12 | 0.170 |
Why?
|
| Aged | 4 | 2021 | 5525 | 0.170 |
Why?
|
| Sleep Hygiene | 1 | 2020 | 1 | 0.160 |
Why?
|
| Anxiety | 1 | 2021 | 157 | 0.160 |
Why?
|
| Los Angeles | 1 | 2020 | 13 | 0.160 |
Why?
|
| Cercopithecus | 1 | 2020 | 2 | 0.160 |
Why?
|
| Growth and Development | 1 | 2020 | 7 | 0.160 |
Why?
|
| Health Risk Behaviors | 1 | 2020 | 7 | 0.160 |
Why?
|
| Allostasis | 1 | 2020 | 5 | 0.160 |
Why?
|
| Bradykinin | 1 | 2019 | 27 | 0.160 |
Why?
|
| Commerce | 1 | 2020 | 54 | 0.160 |
Why?
|
| Alcoholism | 1 | 2021 | 119 | 0.160 |
Why?
|
| Veins | 1 | 2019 | 19 | 0.160 |
Why?
|
| Afferent Pathways | 1 | 2019 | 62 | 0.160 |
Why?
|
| Mobile Applications | 1 | 2020 | 67 | 0.160 |
Why?
|
| Pericardium | 1 | 2019 | 47 | 0.160 |
Why?
|
| Colorado | 3 | 2011 | 51 | 0.160 |
Why?
|
| Social Environment | 1 | 2020 | 56 | 0.160 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 79 | 0.160 |
Why?
|
| Cohort Studies | 1 | 2022 | 893 | 0.160 |
Why?
|
| Sympathetic Nervous System | 1 | 2019 | 68 | 0.160 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2019 | 77 | 0.160 |
Why?
|
| Depression | 1 | 2021 | 222 | 0.150 |
Why?
|
| Sexuality | 1 | 2019 | 4 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1026 | 0.150 |
Why?
|
| Reflex | 1 | 2019 | 74 | 0.150 |
Why?
|
| Gender Identity | 1 | 2019 | 25 | 0.150 |
Why?
|
| Transgender Persons | 1 | 2019 | 11 | 0.150 |
Why?
|
| Hemodynamics | 1 | 2019 | 221 | 0.150 |
Why?
|
| Friends | 1 | 2018 | 14 | 0.140 |
Why?
|
| Placebo Effect | 1 | 2018 | 6 | 0.140 |
Why?
|
| Middle Aged | 5 | 2025 | 7310 | 0.140 |
Why?
|
| Diet | 1 | 2020 | 232 | 0.140 |
Why?
|
| Persuasive Communication | 1 | 2018 | 13 | 0.140 |
Why?
|
| Prognosis | 1 | 2020 | 807 | 0.140 |
Why?
|
| Professional-Patient Relations | 1 | 2018 | 28 | 0.140 |
Why?
|
| Psychological Theory | 1 | 2018 | 30 | 0.140 |
Why?
|
| Family | 1 | 2018 | 98 | 0.140 |
Why?
|
| Models, Psychological | 1 | 2018 | 81 | 0.140 |
Why?
|
| Social Norms | 1 | 2017 | 12 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 461 | 0.130 |
Why?
|
| Cues | 1 | 2017 | 40 | 0.130 |
Why?
|
| Mental Health | 3 | 2024 | 110 | 0.130 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 4 | 0.130 |
Why?
|
| Contraindications | 1 | 2016 | 13 | 0.130 |
Why?
|
| Motivation | 1 | 2018 | 213 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 175 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 734 | 0.120 |
Why?
|
| Exercise | 1 | 2021 | 493 | 0.120 |
Why?
|
| Biomarkers | 1 | 2019 | 770 | 0.120 |
Why?
|
| Child | 1 | 2021 | 2271 | 0.110 |
Why?
|
| Students | 1 | 2017 | 199 | 0.110 |
Why?
|
| Time Factors | 1 | 2018 | 1600 | 0.110 |
Why?
|
| Heterosexuality | 2 | 2024 | 19 | 0.100 |
Why?
|
| Organizational Culture | 1 | 2011 | 25 | 0.090 |
Why?
|
| Oklahoma | 2 | 2025 | 1038 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 78 | 0.080 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 67 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2011 | 123 | 0.080 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2024 | 6 | 0.050 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 15 | 0.050 |
Why?
|
| Marketing | 1 | 2024 | 35 | 0.050 |
Why?
|
| Metformin | 1 | 2004 | 36 | 0.050 |
Why?
|
| Disease Management | 1 | 2004 | 90 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 80 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 45 | 0.050 |
Why?
|
| Smoke | 1 | 2023 | 37 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2019 | 355 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 65 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2004 | 310 | 0.050 |
Why?
|
| Animals | 3 | 2021 | 10580 | 0.050 |
Why?
|
| Body Composition | 1 | 2004 | 266 | 0.050 |
Why?
|
| Logistic Models | 1 | 2022 | 409 | 0.050 |
Why?
|
| Pan paniscus | 1 | 2021 | 1 | 0.040 |
Why?
|
| Pongo | 1 | 2021 | 1 | 0.040 |
Why?
|
| Pan troglodytes | 1 | 2021 | 13 | 0.040 |
Why?
|
| Hominidae | 1 | 2021 | 11 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 55 | 0.040 |
Why?
|
| Cercopithecidae | 1 | 2020 | 1 | 0.040 |
Why?
|
| C-Peptide | 1 | 2020 | 8 | 0.040 |
Why?
|
| Grooming | 1 | 2020 | 3 | 0.040 |
Why?
|
| Receptors, Bradykinin | 1 | 2019 | 1 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2019 | 32 | 0.040 |
Why?
|
| Competitive Behavior | 1 | 2020 | 17 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 34 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 115 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2020 | 108 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 114 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2019 | 172 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 554 | 0.040 |
Why?
|
| Heart Rate | 1 | 2019 | 380 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 622 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 1587 | 0.030 |
Why?
|
| Body Constitution | 1 | 2004 | 11 | 0.010 |
Why?
|
| Health Services Research | 1 | 2004 | 43 | 0.010 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2004 | 10 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 48 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 60 | 0.010 |
Why?
|
| Arginine | 1 | 2004 | 42 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 50 | 0.010 |
Why?
|
| Testosterone | 1 | 2004 | 72 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 250 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 421 | 0.010 |
Why?
|
| Lipids | 1 | 2004 | 214 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2004 | 176 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 301 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 340 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 2402 | 0.010 |
Why?
|